SCHEMBL325210

SCHEMBL325210

CC(C)(C)COC(=O)N1C=Cc2ccccc2C1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.38
HSD17B3 P37058 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
P2RX4 Q99571 3/20 0.33
CSNK1A1 P48729 1/20 0.32
NAMPT P43490 1/20 0.32
MAPK1 P28482 1/20 0.32
NOTUM Q6P988 1/20 0.32
NR1H2 P55055 2/20 0.32
HTR2A P28223 4/20 0.31
HTR2C P28335 4/20 0.31
HRH1 P35367 4/20 0.31
HTR2B P41595 4/20 0.31
HSP90AA1 P07900 1/20 0.31
RIPK1 Q13546 2/20 0.31
NR1H3 Q13133 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29493251 0.86 HDAC3 (0.41) HDAC3HSD17B3NAMPTMAPK1HSP90AA1
SCHEMBL15056964 0.86 HDAC3 (0.41) HDAC3HSD17B3NAMPTMAPK1HSP90AA1
SCHEMBL15056675 0.83 HDAC3 (0.36) HDAC3HSD17B3P2RX4NAMPTMAPK1
SCHEMBL5721697 0.82 ALDH1A1 (0.41) HDAC3HSD17B3P2RX4NAMPTMAPK1
SCHEMBL323681 0.82 MAPK1 (0.45) HDAC3HSD17B3NAMPTMAPK1NR1H2
SCHEMBL15056981 0.81 HDAC3 (0.35) HDAC3HSD17B3P2RX4NAMPTHTR2A
SCHEMBL323769 0.81 TSHR (0.42) HDAC3HSD17B3P2RX4NAMPT
SCHEMBL324125 0.81 P2RX4 (0.53) HDAC3HSD17B3P2RX4NAMPTMEN1
SCHEMBL324190 0.80 BCHE (0.44) HDAC3NAMPTMAPK1MEN1KMT2A
SCHEMBL3628702 0.80 P2RX4 (0.46) HDAC3HSD17B3P2RX4NAMPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 HDAC3 2109/4885HSD17B3 967/4885DPP8 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.